Segment Information (Tables)

3 Months Ended

Mar. 31, 2017

The following table summarizes the Company’s revenue by segment:

	Three Months Ended March 31,
(in thousands)	2017		2016
Revenue:
MRI revenue		49,455	$	47,570
PET/CT revenue		32,180		31,666
Other radiology		6,177		6,403
Radiology		87,812		85,639
Oncology		30,033		26,062
Interventional		11,652		11,663
Corporate / Other		439		361
Total	$	129,936	$	123,725

Summary of Adjusted EBITDA By Segment

The following table summarizes the Company’s Adjusted EBITDA by segment:

	Three Months Ended March 31,
(in thousands)	2017			2016
Adjusted EBITDA:
Radiology	$	29,205		$	26,443
Oncology		13,808			12,157
Interventional		1,055			1,255
Corporate / Other		(11,310	)		(9,483	)
Total	$	32,758		$	30,372

Reconciliation of Income Before Income Taxes, Earnings From Unconsolidated Investees, and Noncontrolling Interest to Total Adjusted EBITDA

The reconciliation of income before income taxes, earnings from unconsolidated investees, and noncontrolling interest to total Adjusted EBITDA is shown below:

	Three Months Ended March 31,
(in thousands)	2017			2016
Income before income taxes, earnings from unconsolidated investees, and noncontrolling interest	$	4,122		$	2,205
Earnings from unconsolidated investees		336			252
Interest expense, net		8,700			7,495
Depreciation expense		14,073			13,048
Amortization expense		3,275			2,443
Share-based payment (included in “Selling, general and administrative expenses”)		381			1,865
Severance and related costs		634			1,716
Restructuring charges (Note 3)		215			231
Transaction costs		162			417
Shareholder transaction costs		869			1,009
Legal matters expense, net (included in “Selling, general and administrative expenses”)		—			155
Changes in fair value of contingent consideration related to acquisitions (included in “Other income, net”)		—			(600	)
Other non-cash (benefits) charges, net (included in “Other income, net”)		(9	)		136
Total Adjusted EBITDA	$	32,758		$	30,372

Summary of Identifiable Assets By Segment

The following table summarizes the Company’s identifiable assets by segment:

	March 31,		December 31,
(in thousands)	2017		2016
Identifiable assets:
Radiology	$	290,480	$	301,137
Oncology		251,382		256,456
Interventional		81,288		82,221
Corporate / Other		22,492		20,050
Total	$	645,642	$	659,864

Summary of Capital Expenditures By Segment

The following table summarizes the Company’s equipment capital expenditures by segment:

	Three Months Ended March 31,
(in thousands)	2017		2016
Capital expenditures:
Radiology	$	812	$	16,926
Oncology		12		484
Interventional		15		33
Corporate / Other		—		232
Total	$	839	$	17,675